Naltrexone is under clinical development by Allodynic Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Naltrexone’s likelihood of approval (LoA) and phase transition for Psychiatric Disorders took place on 13 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Naltrexone Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Naltrexone overview

Naltrexone is under development for the treatment of postherpetic neuralgia, chronic low back pain, migraine, adjustment disorder (emotional pain). The drug candidate acts by targeting opioid receptors.

Quick View Naltrexone LOA Data

Report Segments
  • Innovator
Drug Name
  • Naltrexone
Administration Pathway
Therapeutic Areas
  • Central Nervous System
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.